Chris Dokomajilar on Trends in Life Science Investing, M&A and Partnering

from Rx for Biotech · host Podcast Host Chris Leidli

The biopharma ecosystem is devoting significant resources to develop novel cell and gene therapies to treat cancer. In this episode of "Rx for Biotech", Chris Dokomajilar discusses trends in Biotechnology investment, licensing and partnering landscape and provides an outlook on what to expect for the remainder of 2022.

Episode metadata supplied by the publisher feed · Published May 23, 2022

Embed this episode

Attribution link and audio player

NOW PLAYING

Chris Dokomajilar on Trends in Life Science Investing, M&A and Partnering

0:00 24:17

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

Wild WinsDay Wild WinsDay Pump the hump with WILD WINSday 🐪💪: Your 3-minute weekly video boost for leadership, sales, marketing, and business breakthroughs to WIN the day!

Frequently Asked Questions

How long is this episode of Rx for Biotech?

This episode is 24 minutes long.

When was this Rx for Biotech episode published?

This episode was published on May 23, 2022.

Can I download this Rx for Biotech episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!